Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 27, 2015 5:13 AM ET

Biotechnology

Company Overview of ProFibrix, BV.

Company Overview

ProFibrix, BV. develops and markets products for hemostasis and regenerative medicine markets. It offers Fibrocaps, a dry powder topical fibrin sealant based on a mixture of fibrinogen and thrombin, which helps to stop bleeding during surgery and after trauma injury. The company offers its products based on human fibrinogen, a natural blood protein for blood clotting and tissue healing. ProFibrix, BV. was founded in 2004 and is based in Leiden, the Netherlands with a subsidiary and office in Seattle, Washington. It has a manufacturing site in the United Kingdom. As of August 5, 2013, ProFibrix, BV. operates as a subsidiary of The Medicines Company.

Darwinweg 24

Leiden,  2333 CR

Netherlands

Founded in 2004

Phone:

31 88 730 8301

Fax:

31 88 730 8383

Key Executives for ProFibrix, BV.

Chief Executive Officer, President and Chief Operating Officer
Age: 57
Vice President of Finance
President of Profibrix Inc
Chief Medical Officer
Chief Business Officer
Compensation as of Fiscal Year 2014.

ProFibrix, BV. Key Developments

ProFibrix B.V. Completes Enrolment of its Pivotal Phase III Clinical Trial with Fibrocaps

ProFibrix B.V. announced that the company has completed enrolment of its pivotal Phase III clinical trial with Fibrocaps (FINISH-3) on schedule. FINISH-3 is a multicenter, randomized, single-blind, controlled Phase III trial of Fibrocaps in surgical patients with mild to moderate surgical bleeding. Participating surgeons enrolled a total of 718 patients in only 10 months. The main objectives of the study are to demonstrate superior efficacy of Fibrocaps vs. gelatin sponge within four surgical indications, and to confirm the overall safety results from the Phase II Fibrocaps trials. Final study results are expected to be announced in the summer of 2013. Fibrocaps is a mixture of two essential blood clotting proteins, fibrinogen and thrombin, formulated as a unique dry powder topical fibrin sealant, which is being developed to stop bleeding during or after surgery. Fibrocaps is clearly differentiated from existing liquid fibrin sealants and hemostats: it is ready for immediate use, and is stable at room temperature.

Similar Private Companies By Industry

Company Name Region
Mart Microbiology B.V. Europe
Amphera B.V. Europe
Antimmune BV Europe
Xenikos B.V. Europe
MICREOS Food Safety BV Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ProFibrix, BV., please visit www.profibrix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.